12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 February 2025
Benralizumab for previously treated severe nasal polyps [ID1659]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitisStatus:In development | In consultationProgramme:Interventional procedures guidanceConsultation end date: 26 September 2024Expected publication date: 5 February 2025
Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
PROPEL (mometasone furoate implant, 370ug) MT578 (MIB253)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) (TA972)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 May 2024
Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older [ID6440]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC